Fig. 1: Outcomes for VRd and Rd. | Blood Cancer Journal

Fig. 1: Outcomes for VRd and Rd.

From: Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Fig. 1

a Progression-free survival (N = 460). b Response duration (N = 357). c Overall survival (N = 460). d Overall survival (OS) at 5 years.

Back to article page